This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the genetics of breast and ovarian cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
The chronic myeloproliferative disorders consist of chronic myelogenous leukemia, polycythemia vera (p. vera), primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. All of these disorders involve dysregulation at the multipotent hematopoietic stem cell (CD34), with one or more of the following shared features:
Overproduction of one or several blood elements with dominance of a transformed clone.
Hypercellular marrow/marrow fibrosis...
This summary is reviewed regularly and updated as necessary by the PDQ Cancer Genetics Editorial Board. Board members review recently published articles each month to determine whether an article should:
be discussed at a meeting,
be cited with text, or
replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Genetics of Breast and Ovarian Cancer are:
Kathleen A. Calzone, PhD, RN, APNG, FAAN (National Cancer Institute)
Ilana Cass, MD (Cedars-Sinai Medical Center)
Mary B. Daly, MD, PhD (Fox Chase Cancer Center)
Susan Domchek, MD (University of Pennsylvania Cancer Center)
Donald W. Hadley, MS, CGC (National Human Genome Research Institute)
Jennifer Lynn Hay, PhD (Memorial Sloan-Kettering Cancer Center)
Karen H. Lu, MD (University of Texas, M.D. Anderson Cancer Center)
Suzanne M. O'Neill, MS, PhD, CGC (Northwestern University)
Tuya Pal, MD, FAAP, FABMG (H. Lee Moffitt Cancer Center & Research Institute)
Susan K. Peterson, PhD, MPH (University of Texas, M.D. Anderson Cancer Center)
Mark E. Robson, MD (Memorial Sloan-Kettering Cancer Center)
Jeffery P. Struewing, MD (National Human Genome Research Institute)
Susan T. Vadaparampil, PhD, MPH (H. Lee Moffitt Cancer Center & Research Institute)
Catharine Wang, PhD, MSc (Boston University School of Public Health)
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Cancer Genetics Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary]."